NCT04532268View on ClinicalTrials.gov

A Study of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell ALL and B-cell NHL

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

August 23, 2020

Primary Completion Date

August 23, 2023

Study Completion Date

August 23, 2026

Conditions
Acute Lymphoblastic LeukemiaNon-hodgkin Lymphoma,B Cell
Interventions
DRUG

Humanized CD19 CAR-T cells

Each subject receive humanized CD19 CAR T-cells by intravenous infusion

Trial Locations (1)

310003

RECRUITING

The First Affiliated Hospital，College of Medicine, Zhejiang University, Hangzhou

All Listed Sponsors
collaborator

Yake Biotechnology Ltd.

INDUSTRY

lead

Zhejiang University

OTHER